Bacteremia in patients receiving TNF-alpha antagonists – A prospective multicenter study
Authors:
- Pierre LoulerguePLPierre Loulergue
- Florence TubachFTFlorence Tubach
- Dominique SalmonDSDominique Salmon
- Pierre DellamonicaPDPierre Dellamonica
- Bruno TaillanBTBruno Taillan
- Jean-Baptiste ThorelJTJean-Baptiste Thorel
- Philippe MarteauPMPhilippe Marteau
- Christian BressotCBChristian Bressot
- Philippe RavaudPRPhilippe Ravaud
- Xavier MarietteXMXavier Mariette
- Olivier LortholaryOLOlivier Lortholary
- 1 December 2013
- journal article
- research article
- Published by Elsevier in Journal of Infection
- Vol. 67 (6) , 524-528
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)Annals of the Rheumatic Diseases, 2010
- Risk of tuberculosis is higher with anti–tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three‐year prospective french research axed on tolerance of biotherapies registryArthritis & Rheumatism, 2009
- Emergence of Legionella pneumophila Pneumonia in Patients Receiving Tumor Necrosis Factor- AntagonistsClinical Infectious Diseases, 2006
- Rates of serious infection, including site‐specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics RegisterArthritis & Rheumatism, 2006
- Infections in patients with rheumatoid arthritis treated with biologic agentsArthritis & Rheumatism, 2005
- Infections Associated With Tumor Necrosis Factor-α AntagonistsMedicine, 2005
- Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trialThe Lancet, 2004
- Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapyRheumatology, 2003
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trialThe Lancet, 1999